T he extracellular matrix (ECM) protein elastin constitutes about 30% of the dry weight of the arteries. Elastolysis induced by inflammatory processes is active in chronic arterial diseases, notably atherosclerosis 1,2 and abdominal aortic aneurysm (AAA). [3] [4] [5] However, elastogenesis (ie, the de novo synthesis of elastin) in arterial diseases has received much less attention. 6 Elastin production begins with the synthesis and secretion of the soluble precursor tropoelastin. Different isoforms (67.5 kDa, 65 kDa, and 62 kDa) arise from translation of alternatively spliced mRNA transcripts. 7, 8 Microfibrillar components create a "scaffold" onto which the tropoelastin is attached. Subsequent cross-linking by lysyl oxidase yields insoluble amorphous elastin containing the rare amino acids desmosine and isodesmosine. Binding of a protective 67-kDa elastin-binding protein to both elastin and its precursor tropoelastin partially mediates the extraordinary stability of this matrix molecule. 9 Of the microfibrillar proteins, fibrillin-2 participates in early elastogenesis 10 and microfibril-associated glycoprotein 1 associates with tropoelastin. Loss of medial functional elasticity as a result of reduced elastin expression increases luminal wall stress and increases the possibility of endothelial damage and a predisposition to atherosclerosis. 11 The age dependency of elastin biosynthesis remains controversial, with some studies showing either age-independent synthesis [12] [13] [14] [15] or lack of elastin turnover with age. 16 A putative elastin-laminin receptor on monocytes in atherosclerotic plaques 17 may mediate cell death by apoptosis or by oncosis. 18 Impaired elastogenesis, or disruption of the elastin gene, contributes to human disorders, such as supravalvular aortic stenosis, 19 cutis laxa, 20 Hurler disease, 21 and Costello syndrome. 22 Targeted inactivation of the elastin gene has established an essential role for elastin in arterial morphogenesis. 23, 24 Homozygous elastin-deficient mice die of obstructive arterial disease after birth, 23 whereas the arteries of mice with one allele for elastin show increased elastic lamellae. 24 During arterial development, the number of elastic lamellae increases. 24 Alterations in elastin content also accompany atherosclerotic plaque development, 25 flow-induced dilatation, 26 and nonatherosclerotic intimal thickening. 27 Several pathological stimuli may evoke elastogenesis, 28 -30 for example, reduplication of elastic lamellae in healed arteritis and some atheroma.
We therefore hypothesized that dysregulated synthesis of elastin accompanies atherogenesis and aneurysm formation, processes that were heretofore associated with elastin breakdown. This study investigated the expression of elastin in arterial diseases and of tropoelastin in human macrophages (M⌽) in vitro. Our results showed augmented elastogenesis during both atheroma and AAA formation but favoring accumulation of immature rather than fully processed and cross-linked elastin. AAA particularly showed this defect in elastin maturation. We also identified macrophages as a novel source for elastin. These results have considerable import for understanding mechanisms of ECM remodeling in arterial diseases.
Materials and Methods

Cell Culture
Monocytes isolated from leukopacs of healthy donors (nϭ4) by density gradient centrifugation (Cappel LSM Lymphocyte Separation Media, ICN Biomedical Inc., Aurora, Ohio) were cultured up to 14 days in RPMI-1640 (Gibco BRL, Gaithersburg, Md) containing 100 U/mL penicillin/streptomycin, 2 mmol/L L-glutamine, 1.26 mg/mL amphotericin B, 20 mmol/L sodium pyruvate, 0.1% NaHCO 3 supplemented with 2% human serum and 10% fetal bovine serum. All media contained less than 40 pg endotoxin/mL as determined by the chromogenic Limulus Amebocyte Assay (Cambrex Biosciences, Walkersville, Md).
Tissue Samples
We obtained fresh surgical specimens of human carotid atheroma, nonatherosclerotic aorta (cardiac transplantation donors), as well as discarded aneurysmal tissue from AAA repair surgery according to protocols approved by the Human Investigation Review Committee at the Brigham and Women's Hospital. Atherosclerotic plaques were dichotomized into fibrous (nϭ4) and atheromatous (nϭ5) subsets by morphological criteria as described previously. 31 Specimens from nonatherosclerotic and AAA tissue contained the entire artery wall, whereas endarterectomy specimens (atherosclerotic plaques) only contained the intima and part of the media.
Immunohistochemistry
Serial cryostat sections (6 m) of tissue from nonatherosclerotic arteries (nϭ4), fibrous (nϭ4), and atheromatous (nϭ5) plaques, as well as AAA (nϭ5), were fixed in acetone (Ϫ20°C for 5 minutes) and blocked with 0.3% hydrogen peroxide for 20 minutes at room temperature followed by 5% species-appropriate normal serum (Vector Laboratories, Burlingame, Calif). Subsequently, sections were incubated for 30 minutes with primary antibodies GA317 1:20 (Elastin Products, Owensville, Mo) and/or monoclonal mouse antihuman elastin E4013 1:10 (Sigma, Saint Louis, Mo) and processed according to the manufacturer's recommendations (LSAB kit, DAKO, Carpinteria, Calif). Competition experiments with or without insoluble bovine elastin and chicken tropoelastin verified the specificity of both antibodies (data not shown). Mouse IgG1 (M-9269; Sigma) and rabbit IgG1 (SC-2027; Santa Cruz Biotechnology Inc., Santa Cruz, Calif) at the same concentration as the primary antibodies served as negative controls. The reaction was visualized with 3-amino-9-ethyl carbazole. For double immunostaining, tissue sections were incubated with primary antihuman tropoelastin (GA 317) as described above. The tropoelastin-stained sections were treated with an avidin/biotin blocking kit (Vector Laboratories). Cell-type specific mouse antihuman macrophage antibody (CD68, DAKO) 1:500 was applied overnight at ϩ4°C, followed by biotinylated secondary antibody for 45 minutes (Vector Laboratories) and streptavidin-conjugated alkaline phosphatase for 30 minutes and developed with Fast Blue substrate. Double immunofluorescent labeling was applied to M⌽s cultured in 4-well Lab Tek chamber slides (Nunc, Naperville, Ill). Cells were fixed with ice-cold acetone, air-dried, and stored at Ϫ20°C. Antitropoelastin (GA137) 1:400 was applied for 90 minutes followed by biotinylated secondary antibody for 45 minutes and Texas redconjugated streptavidin for 20 minutes (Amersham Pharmacia Biotech UK Ltd., Buckinghamshire, UK). Subsequently, the avidin/ biotin blocking kit (Vector Laboratories) was applied, followed by overnight incubation at ϩ4°C with antihuman macrophage (CD68) 1:500. Finally, biotinylated horse anti-mouse secondary antibody was applied, followed by incubation with streptavidin-FITC (Amersham Pharmacia Biotech).
In Situ Hybridization for Tropoelastin mRNA
To colocalize tropoelastin mRNA with M⌽ in tissues, we studied M⌽-rich shoulder regions of plaques (nϭ4). Sections were fixed with ice-cold acetone and analyzed with the Hyb-Probe Detection System according to the manufacturer's instructions (Shandon/ Lipshaw, Pittsburgh, Pa). Briefly, synthetic 40-mer 5Ј-fluoresceinlabeled oligonucleotide probes were commercially synthesized (IDT, Coralville, Ind). The specificity was verified with the BLAST program (BLASTN. 2.2.2.). 32 Sense probes:
Elastin1481 CONTR (pos. 1481 to 1520) 5Ј-GGGTTAGTTCCTGG-TGTCGGCGTGGCTCCTGGAGTT GGCG-3Ј; Elastin1512 CONTR (pos. 1512 to 1551) 5Ј-GAGTTGGCGTGGC-TCCTGGTGTCGGTGTGGCTCCTGGAGT-3Ј; Elastin1584 CONTR (pos. 1584 to 1623) 5Ј-GAGTTGGTGTGGC-TCCTGGCGTTGGCGTGGCTCCCGGCAT-3Ј.
Antisense probes:
Elastin1481 5Ј-CGCCAACTCCAGGAGCCACGCCGACACCAG-GAACTAACCC-3Ј; Elastin1512 5Ј-ACTCCAGGAGCCACACCGACACCAGGAGCC-ACGCCAACTC-3Ј; Elastin1584 5Ј-ATGCCGGGAGCCACGCCAACGCCAGGAGCC-ACACCAACTC-3Ј. Positions refer to the cDNA sequence of elastin (GenBank M36860).
Either three antisense or three sense probes (4 g/mL each probe) were applied simultaneously to the tissue sections. The mRNA signal was detected by an antifluorescein antibody and alkaline phosphatase with NBT/BCIP chromogen solution. Tissues were counterstained with Contrast Red (Kirkegaard & Perry Laboratories, Gaithersburg, Md). To colocalize tropoelastin mRNA with M⌽, the same tissue sections were subsequently stained with CD68 (as above). For cultured M⌽, the tropoelastin mRNA signal was detected using alkaline phosphatase and NAMP/Fast Red substrate (Sigma) without counterstain. Negative controls were preincubated with 2 g/L RNase (Sigma) for 1 hour at 37°C before hybridization with antisense probes, or samples incubated either without probe or with sense probe.
Western Blot
Tissue extracts from nonatherosclerotic (nϭ8), fibrous (nϭ7), and atheromatous (nϭ9) plaques and from AAA (nϭ7) were prepared as described previously. 33 Supernatants were removed from cultured M⌽ and supplemented with the following proteinase inhibitors: 0.1 mmol/L 4-(2-aminoethyl) benzenesulfonyl fluoride Hydrochloride, 2 g/mL aprotinin, 2 g/mL leupeptin, and 1 g/mL pepstatin A. Fifty micrograms of total protein per sample was analyzed under reducing conditions on 8% SDS-PAGE gels and transferred to polyvinylidene fluoride membranes as described. 34 The primary antibody was antihuman elastin (E4013) 1:500, and the secondary antibody was peroxidase-conjugated goat antimouse IgG (Jackson ImmunoResearch Laboratories, West Grove, Pa) 1:10,000. Immunoreactive bands were analyzed densitometrically using Gel Pro Analyzer Software (Media Cybernetics Inc., Des Moines, Ia). All results were normalized to total protein. Reverse transcriptase protocol: 10 minutes at 20°C, 15 minutes at 42°C, and 5 minutes at 99°C. Amplification protocol: 95°C at 2 minutes and then 36 cycles at 95°C for 1 minute, 64°C for 1 minute, and 72°C for 1 minute. PCR products (elastin 319 bp) were run on 1% agarose gels, stained with ethidium bromide, and analyzed as above.
Desmosine Analysis
M⌽ from two donors was differentiated for 7 and 14 days and smooth muscle cells (SMCs; as positive control, nϭ2) were cultured for 7 days postconfluency (day 14 in culture). Cells were washed two times in PBS, and then cells and matrix were removed by scraping into 1 mL of distilled water. Samples were centrifuged for 5 minutes at 300g and pellets resuspended in 6 N HCl. Tissue samples from normal (nϭ3), fibrous (nϭ3,) and atheromatous (nϭ3) plaques and from AAA (nϭ3) were dissolved in 6 N HCl and hydrolyzed overnight at 110°C. Desmosine levels were determined by radioimmunoassay 35 and normalized to total protein. 36 
Statistics
Results were analyzed with the nonparametric Mann-Whitney test. Probability values of Յ0.05 (two-tailed tests) were regarded as statistically significant.
Results
Elevated Tropoelastin Levels in Human Atheroma and AAA
We found soluble tropoelastin protein in tissue extracts from normal artery, fibrous plaque, atheromatous plaque, and AAA by Western blotting using antihuman elastin antibody E4013. The predominant band migrated as the 67.5-kDa isoform ( Figure  1A ). Compared with normal arteries (nϭ8), fibrous plaques and atheromatous plaques had 3-fold (nϭ7; Pϭ0.011) and 6-fold (nϭ9; Pϭ0.001) higher tropoelastin levels ( Figure 1B ). This elevated expression likely underestimates the actual increase because these samples did not contain the adventitia. Extracts from AAA showed a 5-fold increase compared with normal aortic tissue (nϭ7; Pϭ0.001). Antitropoelastin antibody GA317 yielded similar results (data not shown).
Increased Tropoelastin Levels in Human Atheroma and AAA In Situ
Normal arteries had well-ordered elastin (Figure 2A, top) . However, atheromatous tissue showed abundant but frequently disordered elastin (Figure 2A Verhoeff-van Gieson staining of AAA tissue showed occasional fragmented elastin fibers but no organized elastic laminae (see online Figure I , which can be accessed at http://atvb.ahajournals.org). These tissues contained scattered M⌽ but almost no SMCs. Abundant tropoelastin, which was visualized with antitropoelastin GA317, localized mainly in M⌽-rich areas, whereas antielastin E4013 showed little staining. This finding suggests that tropoelastin and not mature elastin generates the signal observed in AAA tissue. Some acellular regions contained sparse elastin that may, given the paucity of cells, represent elastin formed earlier in the disease (data not shown). Lack of staining by mouse or rabbit IgG1 (data not shown) verified the specificity of the elastin/tropoelastin signal.
Macrophages: A Novel Source of Tropoelastin
Tropoelastin protein colocalized with M⌽ by single and double immunostaining of serial sections from human atheroma ( Figure 2B ). CD68 (blue color, Figure 2B , top right) and GA317 (red color, Figure 2B , bottom right) gave a mixed purple color when stained for both antigens ( Figure 2B, left) .
Normal tissue had low levels of tropoelastin mRNA ( Figure 3 , top left) whereas the M⌽-rich shoulders of atheromatous plaques displayed abundant tropoelastin mRNA (Figure 3 , right panels). Sense probes yielded no specific signal (Figure 3 , bottom left). Colocalization of the M⌽ marker CD68 (redbrown signal) with tropoelastin mRNA (purple signal) verified that M⌽ can indeed transcribe the gene (see online Figure II , which can be accessed at http://atvb.ahajournals.org).
In vitro experiments extended these observations: primary human monocyte-derived M⌽, cultured for 10 days, expressed tropoelastin mRNA as determined by both in situ hybridization and RT-PCR ( Figure 4A and 4B) , whereas freshly isolated monocytes (1 day in culture) did not (data not shown). Negative controls using sense oligonucleotides ( Figure 4A ) and RNAsetreated samples or no oligonucleotide (see online Figure III , which can be accessed at http://atvb.ahajournals.org) showed no signal.
Double immunofluorescent staining of M⌽ cultured for 10 days verified that a subset of M⌽ produce tropoelastin protein ( Figure 4C ). This observation agrees with localization of tropoelastin mRNA in situ (Figure 3 ). During differentiation in vitro, M⌽ release soluble tropoelastin from days 3 through 12 ( Figure 4D ). 
Biochemical Analysis of Desmosine Content Suggests the Presence of Cross-Linked Elastin in Diseased Arterial Tissue and Cell Cultures
When elastin assembles in vivo to form elastic fibers, extensive cross-linking yields a mature insoluble polymer that contains the rare amino acids desmosine and isodesmosine. Measurement of desmosine by radioimmunoassay determined whether M⌽ could cross-link tropoelastin in vitro. Human monocyte-derived M⌽ contained cross-linked elastin as determined by low but detectable levels of desmosine (6 pmol/mg protein), which were 6-fold less than desmosine levels in SMCs. Extracts from normal and diseased arterial tissue ( Figure 5 ) showed higher desmosine levels in normal tissue (6529Ϯ707 pmol/mg protein) than in fibrous (3800Ϯ455 pmol/mg protein) or atheromatous plaques (3995Ϯ984 pmol/mg protein) or AAA (721Ϯ102 pmol/mg protein). Atheroma contained substantial desmosine although less than in normal tissue. Fibrous but not atheromatous plaques had a significant 1-to 7-fold reduction in desmosine (Pϭ0.050). However, AAA tissue contained 9-fold less desmosine than unaffected arteries (Pϭ0.050). This reduction in desmosine content indicates a paucity of mature, functional elastin in AAA, which may favor arterial ectasia.
Discussion
We provide here morphological, biochemical, and molecular evidence for ongoing but ineffective elastogenesis in human atheroma and AAA. Interestingly, these tissues expressed the precursor tropoelastin in M⌽-rich areas. These results may underestimate the actual tropoelastin expression because atherosclerotic plaques, harvested by endarterectomy, only contain part of the elastin-rich medial layer.
Previous morphological studies demonstrated duplicated elastic lamellae 25, 26 and signs of elastogenesis 6, 37 in atheroma. Early studies established a role for elastin in atherosclerosis. 14, 15 However, the cellular and molecular mechanisms of dysfunctional elastogenesis have received little attention.
This study identified the human M⌽ as an unexpected source of tropoelastin. Studies of tropoelastin protein and mRNA, both in vitro and in situ, verified this new function of mononuclear phagocytes. Immunohistochemical staining of elastin/tropoelastin protein in M⌽-rich areas could reflect signals from elastin fragments bound to the putative elastin-laminin receptor, but the detection of tropoelastin mRNA in M⌽ using several indepen- 
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Recently, morphological observations by Xu et al 38 described tropoelastin expression in macrophages in foam cell-rich lesions in hypertensive-hyperlipidemic rabbits. We show here that human M⌽s acquire the capacity to produce both tropoelastin mRNA and soluble elastin protein during cell differentiation in vitro. M⌽ cultures did not elaborate all of the tropoelastin splice forms, although the biological significance of different tropoelastin species remains uncertain. The functional elastic fiber network in vivo may not incorporate all isoforms.
Biochemical analysis of desmosine levels in cultured M⌽ establish not only that M⌽ can synthesize tropoelastin but also that the precursor can undergo cross-linking to form insoluble, mature elastin. Although in vitro M⌽ contain less desmosine than SMCs, the abundance of M⌽ in atheromatous plaques and their occurrence in AAA suggest that M⌽ can contribute to elastogenesis.
Atheromata and AAA showed decreased desmosine content compared with normal arterial tissue, particularly in the case of AAA. Baxter et al 39 showed an increase in collagen and secondary dilutional decrease in elastin content in AAA compared with normal artery and atheroma. Dissecting aneurysms also have reduced desmosine. 40 The decrement in desmosine in AAA tissue may result from a reduction in total elastin and/or failure of maturation of precursor tropoelastin, which lacks this amino acid. Compared with normal human arteries, AAA have increased tropoelastin levels that are not accompanied by increased desmosine levels, as in rats with experimental AAA. 41 In addition, AAA have sparse cross-linked elastin (revealed by Verhoeff-van Gieson and antibody E4013), suggesting a socalled "maturation arrest" of elastogenesis. This maturation arrest could result from reduced expression or absence of the cross-linking enzyme lysyl oxidase or any of the components of the microfibrillar scaffold that are needed to create the elastic fiber. Recently, Huffman et al 41 showed decreased lysyl oxidase expression in experimental abdominal aortic aneurysm. Inactivation of the lysyl oxidase gene in mice leads to aortic aneurysms and cardiovascular dysfunction. 42 Thus, an increase in tropoelastin synthesis in AAA proves futile as elastin maturation fails and elastolysis predominates.
Surprisingly, both human fibrous and lipid-rich atheroma showed a 1.6-fold reduction in desmosine compared with normal arteries. Atheromatous plaques generally contain fewer matrix-producing cells and less ECM than fibrous plaques. Thus, mechanisms for preserving elastin operate to greater extent in atheroma than in AAA. Very recent observations show enhanced lysyl oxidase mRNA in transgenic atherosclerotichypertensive rats. 43 Desmosine levels decline in atherosclerotic aortae of rats. 44 However, the decreased desmosine level in atheroma compared with overall increased levels of tropoelastin suggest that the increased expression of tropoelastin does not correspond directly to the formation of cross-linked elastin. Much of the increased tropoelastin levels in these tissues may derive from M⌽, which appear to produce only partly crosslinked tropoelastin. Proteoglycan accumulation in atheroma may prevent tropoelastin integration into the functional elastic fiber. 21 The presence of LDL downregulates lysyl oxidase in vascular endothelial cells and the arterial wall of hypercholesterolemic pigs. 45 The present study documents ongoing but often-ineffective elastogenesis in both human atherosclerotic disease and AAA formation. AAA particularly showed this defect in elastin maturation. We also identify M⌽ as a novel source for this matrix protein. These results have considerable import for understanding mechanisms of ECM remodeling in arterial diseases.
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